Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia.

Abstract

Fungal infections due to Aspergillus are a frequent cause of transplant-related mortality. For this reason, leukemic patients with severe fungal infection are usually excluded from conventional allotransplantation. Recently, some authors suggested a role for non-myeloablative hematopoietic stem cell transplantation (HSCT) in this subset of patients. We used this therapeutic approach in a patient with high-risk acute myeloid leukemia in second complete remission (CR) with pre-existing hepatic aspergillosis refractory to conventional anti-fungal therapy. A complete regression of hepatic lesions was observed after 3 months from allogeneic stem cell transplantation. Our work confirms previous reports suggesting that non-myeloablative HSCT is effective in patients not eligible for conventional transplantation because of invasive aspergillosis.

• Authors: Giuseppe Marotta, Monica Tozzi, Simona Sammassimo, Marzia Defina, Donatella Raspadori, Alessandro Gozzetti, Francesco Lauria
• Journal: Hematology (Amsterdam, Netherlands) (Hematology) Vol. 10 Issue 5 Pg. 383-6 (Oct 2005) ISSN: 1024-5332 [Print] England
• PMID: 16273726 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifungal Agents

Topics

• Adult
• Antifungal Agents (therapeutic use)
• Aspergillosis (diagnostic imaging, drug therapy, microbiology)
• Female
• Hematopoietic Stem Cell Transplantation (methods)
• Humans
• Leukemia, Myeloid, Acute (complications, microbiology, therapy)
• Liver (diagnostic imaging, microbiology)
• Liver Diseases (diagnostic imaging, drug therapy, microbiology)
• Male
• Radiography
• Transplantation Conditioning (methods)